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ABSTRACT We investigated the origins of greater clot rigidity associated with FXIIIa-dependent cross-linking. Fibrin clots
were examined in which cross-linking was controlled through the use of two inhibitors: a highly specific active-center-directed
synthetic inhibitor of FXIIIa, 1,3-dimethyl-4,5-diphenyl-2[2(oxopropyl)thio]imidazolium trifluoromethylsulfonate, and a patient-
derived immunoglobulin directed mainly against the thrombin-activated catalytic A subunits of thrombin-activated FXIII.
Cross-linked fibrin chains were identified and quantified by one- and two-dimensional gel electrophoresis and immunostain-
ing with antibodies specific for the - and -chains of fibrin. Gamma-dimers, -multimers, n-polymers, and pq-hybrids
were detected. The synthetic inhibitor was highly effective in preventing the production of all cross-linked species. In contrast,
the autoimmune antibody of the patient caused primarily an inhibition of -chain cross-linking. Clot rigidities (storage moduli,
G) were measured with a cone and plate rheometer and correlated with the distributions of the various cross-linked species
found in the clots. Our findings indicate that the FXIIIa-induced dimeric cross-linking of -chains by itself is not sufficient to
stiffen the fibrin networks. Instead, the augmentation of clot rigidity was more strongly correlated with the formation of
-multimers, n-polymers, and pq-hybrid cross-links. A mechanism is proposed to explain how these cross-linked species
may enhance clot rigidity.
INTRODUCTION
The stabilization of fibrin by activated factor XIII (FXIIIa)
produces remarkable effects on the rheological properties of
clots. This enzymatic process of ligation, often inappropri-
ately referred to in the biochemical literature as cross-
linking (Lorand, 1972), results from the FXIIIa-catalyzed
formation of N-(-glutamyl)lysine isopeptide bonds be-
tween fibrin molecules within clot fibers (Lorand et al.,
1968; Matacic and Loewy, 1968; Pisano et al., 1968). As
shown in Ryan et al., 1999, the architecture of the fibers is
essentially unchanged by these cross-links, though isolated
chemical bonding between fibers that touch each other
would not be visible with electron microscopy. Ligated
clots exhibit mechanical stiffnesses up to five times greater
than their unligated counterparts (Ferry et al., 1951; Roberts
et al., 1973; Gerth et al., 1974; Mockros et al., 1974; Glover
et al., 1975; Shen et al., 1975; Shen and Lorand, 1983) and
do not display the stress-induced structural rearrangements
seen in unligated clots by creep and by permanent defor-
mation after creep recovery (Nelb et al., 1976, 1981; Jan-
mey et al., 1983). The physiological significance of the
FXIIIa-induced clot stabilization is demonstrated clinically
by the severe hemorrhagic tendencies that are often exhib-
ited by patients who suffer from a congenital absence of the
factor XIII zymogen (Lorand et al., 1980) or who have a
circulating inhibitor, frequently an autoimmune antibody,
directed against some component of the factor XIII system
in plasma (Lorand, 1994). Clots or experimental thrombi
formed in whole human blood show significantly greater
susceptibilities to lytic agents in the presence of competitive
inhibitors of cross-linking (Lorand and Jacobsen, 1962;
Bruner-Lorand et al., 1966; Lorand and Nilsson, 1972); the
same effect can be brought about by blocking the enzymatic
activity of FXIIIa by noncompetitive inhibitors (Samama et
al., 1979; Freund et al., 1994) or by antibodies to factor XIII
(Reed and Lukacova, 1995).
Although factor XIIIa is known to stabilize the clot
network, the mechanism by which this cross-linking reac-
tion augments clot stiffness remains largely undetermined.
Ligations between Lys406 and Glu398 of the -chains of two
adjacent fibrin molecules occur rapidly (Chen and Doolittle,
1971; Doolittle et al., 1971), resulting in the formation of
-dimers (Chen and Doolittle, 1969; McKee et al., 1970)
that could be oriented either longitudinally end-to-end be-
tween fibrin molecules (Fowler et al., 1981; Weisel et al.,
1993; Veklich et al., 1998) or transversally across molecules
of different fibrin strands (Selmayr et al., 1985, 1988; Mo-
sesson et al., 1989, 1995; Siebenlist et al., 1995). Multiple
cross-linking between fibrin -chains results in the forma-
tion of -polymers (McKee et al., 1970; Schwartz et al.,
1971; Sobel et al., 1988; Gron et al., 1992), creating poten-
tially intricate and, as yet, ill-defined arrangements between
fibrin molecules. The enhancement of rigidity in ligated
clots has been attributed mainly to the development of
-polymers, whereas -dimerization is thought to have a
smaller (Glover et al., 1975; Gladner and Nossal, 1983) or
even a negligible (Shen et al., 1974, 1975) effect on clot
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mechanical stiffness. Small percentages of FXIIIa-induced
hybrid pq-ligations (Mosesson et al., 1989; Murthy and
Lorand, 1990; Shainoff et al., 1991; Gron et al., 1993) and
higher-order -chain ligations (-trimers and -tetramers;
Mosesson et al., 1989; Murthy and Lorand, 1990; Shainoff
et al., 1991; Siebenlist and Mosesson, 1992) have also been
observed, but their contributions to clot rigidity have not
previously been considered.
The present investigation was undertaken to study the
effects of the individual ligated species on clot mechanical
behavior. Cross-link formation in fibrin clots was controlled
by using two inhibitors: a highly specific, active-center-
directed synthetic inhibitor of FXIIIa, 1,3-dimethyl-4,5-di-
phenyl-2[(2-oxopropyl)thio]imidazolium trifluoromethyl-
sulfonate (Freund et al., 1994), and a patient-derived
immunoglobulin directed mainly against the thrombin-acti-
vated catalytic A subunits of FXIII (Green et al., 1992;
Lorand et al., 1999). The autoimmune antibody, which had
been implicated in the patient’s recurrent hematomas, in-
hibited mainly the ligating of -chains but not -chains. By
monitoring clot rigidity with a cone and plate rheometer and
evaluating the production of the ligation species of fibrin
chains by one- and two-dimensional gel electrophoresis, a
correlation was sought between the biochemical events cat-
alyzed by FXIIIa and the development of clot rigidity.
MATERIALS AND METHODS
Human fibrinogen (plasminogen free; American Diagnostica, Greenwich,
CT) was dissolved by addition of water, then dialyzed against 4 l of 50 mM
Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA at 4°C, and stored at
80°C. Protein concentration was determined by absorbance at 280 nm
(E1cm
1%  15.1; Mihalyi, 1968). The commercial preparation was contami-
nated by small amounts of FXIII, as judged by the detection of bands of n
and – cross-linked chains in reducing SDS-PAGE after clotting the
fibrinogen (6 M) with human -thrombin (1 NIHU/ml) and CaCl2 (5
mM) for 90 min at 37°C. Human -thrombin (a gift from Dr. J. W. Fenton
II, New York State Department of Health, Albany, NY) was diluted to 500
NIHU/ml in 50 mM Tris-HCl, 150 mM NaCl, pH 7.5 and stored at80°C.
Factor XIII was purified from outdated human CPDA-1 plasma accord-
ing to the procedure of Lorand et al. (1981) and stored in 50 mM Tris-HCl,
1 mM EDTA, 10 KIU/ml Trasylol, pH 7.5 at 4°C. Protein concentration of
the stock solution was determined by absorbance at 280 nm (E1cm
1%  13.8;
Schwartz et al., 1973). Just before experiments, the factor XIII zymogen
(0.33 mg/ml) was preactivated by treatment with human -thrombin
(2 NIHU/ml) in 50 mM Tris-HCl, pH 7.5 for 25 min at room temperature.
The 1,3-dimethyl-4,5-diphenyl-2[(2-oxopropyl)thio]imidazolium trifluoro-
methylsulfonate (L683685, Merck, Sharp and Dohme Research Laborato-
ries, West Point, PA), was dissolved in 50 mM Tris-HCl, pH 7.5 with 1%
DMSO and stored at 20°C at a concentration of 0.5 mM.
Patient and normal IgG were prepared by Pauline Velasco from plasma
by affinity chromatography (GammaBind Plus Sepharose, Pharmacia Bio-
tech, Piscataway, NJ) according to manufacturer’s directions. The IgG was
dialyzed against 10 mM Tris-HCl, 154 mM NaCl, pH 7.5 at 4°C, concen-
trated using a Centricon-30 Concentrator (Amicon, Beverly, MA), and




Electrophoretic experiments were carried out on clots formed from mix-
tures with compositions identical to those used in the rheological studies.
Clots were generated at 21°C or 37°C in 50–250 l reaction mixtures that
typically were comprised of 6 M fibrinogen, 31 nM purified factor XIIIa
supplement, 50 mM Tris-HCl (pH 7.5), 0.3% or 0.4% DMSO, 0–150 M
of the FXIIIa inhibitor, sufficient amounts of NaCl (from a stock of 200
mM) to maintain final ionic strengths within the 0.158–0.161 range, 5 mM
CaCl2, and 3.5 NIHU/ml thrombin. In samples prepared for one-dimen-
sional SDS-PAGE, the ligating reaction was stopped by solubilization in 6
M urea, 40 mM dithiothreitol, and 2% SDS at 37°C for 45 min. Samples
prepared with IgG were thoroughly washed with 25 mM EDTA to remove
the IgG and centrifuged to a pellet before solubilization. Ligations in the
reaction mixtures prepared for isoelectric focusing were stopped by boiling
for 1 min in 5 M urea, 103 mM dithiothreitol, 5% 2-mercaptoethanol, 10%
ampholine pH 3.5–10, and 2.9% Nonidet P-40, followed by exposure to
37°C for 5 h.
One-dimensional SDS-PAGE (8% acrylamide) was performed by the
procedure of Laemmli (1970) in a Mini-Protean II Dual Slab Cell (BioRad,
Hercules, CA). Samples of 6 g protein per lane were analyzed, and a
broad-range molecular weight standard (BioRad) was used for reference.
Two-dimensional polyacrylamide gel electrophoresis was carried out ac-
cording to the method of O’Farrell (1975). Isoelectric focusing in the first
dimension was performed in a Mini-Protean II 2-D Cell (BioRad) with 4.5
g protein samples in ampholine (1.6%) between pH 3.5 and 10. Separa-
tion in the second dimension was carried out by SDS-PAGE (8% acryl-
amide) as described above.
Electroblotting to nitrocellulose (0.2 m pore size, Schleicher and
Schuell, Keene, NH) was performed in a Mini Trans-Blot Electrophoretic
Transfer Cell (BioRad) for 2.5 h at 4°C by the procedure of Towbin et al.
(1979) in 25 mM Tris, 192 mM glycine, 20% methanol. Gels were stained
with Coomassie brilliant blue R (0.025% in 10% acetic acid and 20%
methanol), and amido black (1% in 10% acetic acid and 50% methanol)
was used for staining the nitrocellulose transblots. Photographs of the gels
and transblots in the figures show the protein bands with Mr values higher
than 31,000.
A mouse hybridoma supernatant (Ta 7.1.1) raised (by Dr. Lin Gu of our
Blood Cell Function and Development Program Project) against a tryptic
fragment isolated from the -chain of human fibrin, containing residues
291–348 (by Dr. Gennady Samokhin of Northwestern University), was
used for identifying bands with -chains. The supernatant was used in
1:50,000 dilution after one-dimensional electrophoresis and in 1:10,000
dilution after two-dimensional electrophoresis. Bands containing -chains
were detected with a monoclonal antibody (6/20/5) against residues 392–
406 of the fibrin -chain (a gift from Dr. Bohdan J. Kudryk, New York
Blood Center; 1:40,000 dilution after one-dimensional electrophoresis,
1:9000 dilution after two-dimensional electrophoresis). Unbound sites on
the nitrocellulose blots were blocked with 2% nonfat dry milk powder in 10
mM sodium phosphate, 150 mM NaCl, pH 7.5. An alkaline phosphatase-
conjugated anti-mouse IgG (1:5000 dilution, Sigma, St. Louis, MO,
A-1902) was used as secondary antibody, and binding to the mouse IgG
was detected by application of 0.38 M nitroblue tetrazolium (Sigma) with
0.36 M 5-bromo-4-chloro-3-indolylphosphate (Sigma). To enhance con-
trasts, two-dimensional blots were reprobed with antibodies and developed
by repeating the steps described above. Relative intensities of Coomassie
blue-stained bands were measured in an LKB Ultroscan XL Laser Densi-
tometer (Bromma, Sweden) and quantitated by excising and weighing the
recorded peak areas.
Measurement of clot rigidity
A VOR Rheometer (Bohlin Rheologi, Cranbury, NJ) was used for mea-
suring the rheological properties of clots. Bohlin VOR Rheometer Software
Version 4.05 (Bohlin Reologi AB, Sweden) was used for data collection
and for calculating viscoelastic parameters. Reaction components were
mixed in a 1.5-ml Eppendorf tube with buffer (50 mM Tris-HCl, 100–150
mM NaCl, pH 7.5; 330 l total volume and ionic strength of 0.158–0.161).
After the addition of preactivated factor XIIIa and human -thrombin, the
last step for initiating coagulation, the reaction components were thor-
oughly mixed with a pipette tip, and 325 l of the clotting mixture were
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quickly transferred from the tube to the stainless steel rheometer cone and
plate fixture (which had a 2.5° cone angle and 30 mm diameter). Mea-
surements were taken at 0.1 Hz under an imposed strain of 0.015. For
measuring purposes, the rheometer operated in an oscillatory mode, with
data collected over 10-s periods every 2 min. Between the 2-min intervals
the clot remained at rest. The rheological behavior of clots formed under
oscillatory strains, as in these experiments, did not differ significantly from
those of clots formed without imposed oscillation (data not shown). Sam-
ples were tested at 21°C or 37°C. To prevent dehydration, heavy mineral
oil (Walgreen Co., Deerfield, IL) was applied to a ring surrounding the
exposed surfaces of the clots at the beginning of experiments.
RESULTS
Effect of a patient’s FXIII-directed IgG on clot
rigidity and cross-linking
Reducing SDS-PAGE analysis of fibrinogen clotted with
thrombin and calcium revealed that the amount of FXIII
contaminating the fibrinogen preparation was sufficient to
effect nearly full - and -chain cross-linking after 2 h,
resulting in the development of -dimers and several un-
identified higher-molecular-weight cross-linked species la-
beled X1–X5 (Fig. 1, lane 1). The formation of these ligated
species appeared unaffected by the addition of normal IgG
(3 mg/ml, lane 2). Rheological analysis of samples of the
same compositions as those analyzed by SDS-PAGE re-
vealed that clot rigidity, expressed as storage modulus (G),
was slightly lower in the presence of normal IgG (90.6 
14.5 Pa) than in its absence (106.8  14.2 Pa). In sharp
contrast, the presence of 3 mg/ml of the patient-derived IgG
caused a much larger drop in G (to 49.8  11.6 Pa; p 
0.003). Formation of several of the higher-molecular-weight
cross-linked species, particularly bands X1–X3, was inhib-
ited at this concentration of patient IgG, but -dimerization
was not diminished (lane 3).
More complete inhibition of cross-linking could be ac-
complished with the use of the synthetic inhibitor of FXIIIa,
1,3-dimethyl-4,5-diphenyl-2[2(oxopropyl)thio]imidazolium
trifluoromethylsulfonate (Fig. 1, lanes 4–6). At a concen-
tration of 200 M, this inhibitor prevented the formation of
all higher ligated species (X1–X5) and nearly all of the
-dimers, regardless of whether the normal or the patient
IgG was present. Nevertheless, despite nearly complete
inhibition of cross-linking, average stiffnesses (29.7  5.7
Pa without IgG, 31.1 4.8 Pa with normal IgG, and 40.7
5.4 Pa with patient IgG) were only slightly lower (p 
0.029, 0.033, and 0.144, respectively) than those of samples
inhibited by the patient-derived IgG alone (49.8 11.6 Pa).
Clot rigidities at various initial concentrations of
fibrinogen: influence of the synthetic
inhibitor of FXIIIa
The potency of the synthetic inhibitor is further demon-
strated in its ability to significantly reduce the stiffness of
clots over a wide range of physiological fibrinogen concen-
trations. Increasing the concentration of fibrinogen has been
observed to increase clot rigidity in the presence (Samama
et al., 1963; Kaibara, 1973; Glover et al., 1975; Gerth et al.,
1974; Nelb et al., 1976) as well as in the absence of FXIIIa
(Gerth et al., 1974; Nelb et al., 1976). Fig. 2 shows the
dependence of clot stiffness on fibrinogen concentration
under cross-linking conditions (solid circles) and the three-
fold reduction in clot rigidity produced at all fibrinogen
concentrations in the presence of 2.5 M of the inhibitor
(open circles); e.g., in the presence of the inhibitor, the
stiffness of the clot formed from an FXIIIa-containing mix-
ture with a relatively high concentration of fibrinogen (9
M) was reduced to that of a clot formed from a lower
concentration of fibrinogen (3 M) without the inhibitor.
FIGURE 1 Effect of FXIII-directed IgG on clot rigidity and cross-
linking. Clots were formed at 21°C from solutions of fibrinogen (6 M),
thrombin (3.5 NIHU/ml), CaCl2 (5 mM), DMSO (0.4%), synthetic inhib-
itor of FXIIIa (0 or 200 M), and IgG (0 or 3 mg/ml). Samples having the
same compositions as those tested in the rheometer were analyzed by
reducing SDS-PAGE.
FIGURE 2 Effect of the active-center-directed inhibitor of FXIIIa, 1,3-
dimethyl-4,5-diphenyl-2[2(oxopropyl)thio]imidazolium trifluoromethyl-
sulfonate, on clot rigidity at various initial concentrations of fibrinogen.
Clots were formed at 37°C with mixtures of fibrinogen (3–12 M),
thrombin (0.5 NIHU/ml), CaCl2 (5 mM), and FXIII (31 nM, solid circles)
or inhibitor (2.5 M, open circles); all mixtures contained 1% DMSO.
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Profiles of ligated fibrin chains formed in the
presence of the factor XIIIa inhibitor
The chain patterns of fibrin were examined by gel electro-
phoresis coupled with immunostaining to document the
effects of the synthetic inhibitor on the FXIIIa-catalyzed
reaction. Clots were formed at 37°C in the presence of
varying concentrations of the inhibitor and examined by
reducing SDS-gel electrophoresis after 2 h of clotting (Fig.
3 A). The fibrinogen control revealed a heterogeneity of the
A-chains, consistent with cleavages near the carboxy-
terminal regions (Mills and Karpatkin, 1970; Mosesson et
al., 1972b). Three main monomeric A-species were ob-
served in the Mr range of 52,000–67,000; immunostaining
with an antibody to the -chain (Fig. 3 B) also identified
some A-chain degradation products near the position of
B- and -chains and in some minor bands with Mr values
lower than 47,000. A complete release of fibrinopeptides A
and B occurred in the thrombin-catalyzed conversion of
fibrinogen to fibrin, as demonstrated by the shifts of the A
and B bands to lower Mr values upon conversion to  and
 chains (compare lanes 1 and 2 in Fig. 3 A). The concen-
tration of the FXIIIa used for the cross-linking reaction in
these experiments was clearly sufficient to effect a full
depletion of -monomers (lane 3). Two populations of
ligated -dimers were observed, having electrophoretic mo-
bilities compatible with the formation of – and –
dimers (Francis et al., 1980; Lawrence et al., 1993). Ligated
chains at the top of the stacking gel (marked as X1 in Fig.
3 B) are thought to comprise homologous n-polymers
(McKee et al., 1970; Schwartz et al., 1971; Francis and
Marder, 1987), but due to difficulties in transferring these
chain types in the Western blotting experiments, their ho-
mologous polymeric nature could not be directly confirmed.
Other high-molecular-weight ligated chains above 180 kDa
(designated X2–X5 in Fig. 3 B), which reacted with both the
anti- and anti- antibodies, were also detected. The X5 li-
gated material appeared to be comprised of two separate bands:
the higher-molecular-weight band stained only with the anti-
body to the -chains and the lower one only with the antibody
to the -chains.
Cross-linking of the -chains was particularly sensitive to
the action of the inhibitor (Fig. 3 A). Formation of the
largest polymeric band X1 was completely abolished when
the inhibitor was used at a molar ratio above 3:1 to the
FXIIIa added (i.e., 0.1:0.03 M, lane 4). Production of the
cross-linked bands X2–X5 could be prevented with an in-
hibitor-to-enzyme ratio of 320:1 (i.e., 10 M inhibitor, lane
9). Gamma-dimerization was not affected until the concen-
tration of the inhibitor well exceeded 1 M (i.e., an inhibitor-
to-enzyme ratio 32:1), and150 M of the inhibitor (i.e., a
4800-fold molar excess) was required to reduce the intensity of
the band of -dimers to that seen in the starting fibrinogen
sample. Quantitative evaluations of the changes brought about
by increasing the concentration of the FXIIIa inhibitor, as
obtained from the relevant gel scans, are presented in Fig. 4.
The development of -dimers and bands X1–X5 as a
function of time is presented in Fig. 5. The cross-linked
species formed in the order of their molecular weights, with
the smaller ligations having the fastest rates of appearance.
Compositions of the variety of ligated species were fur-
ther examined by two-dimensional electrophoresis, using
isoelectric focusing in the first dimension and SDS-PAGE
in the second (Fig. 6). Protein staining of the noncross-
linked fibrin control revealed two spots of differing pI
values for the -chain, the weaker of which exhibited a
higher molecular weight and probably corresponds to the
-chain, a variant of the -chain having an extended car-
boxy-terminal sequence and constituting 7–16% of the total
FIGURE 3 Changes in the ligated chain profile of fibrin at increasing concentrations of the synthetic inhibitor of FXIIIa. Clotting proceeded at 37°C for
2 h. The various mixtures (all containing 6 M fibrinogen and 0.3% DMSO) were analyzed by reducing SDS-PAGE. (A) Lane 1: with EDTA (1 mM);
lane 2: thrombin (3.5 NIHU/ml), FXIIIa (31 nM), and EDTA (1 mM); lanes 3–13: thrombin, FXIIIa, CaCl2 (5 mM), and inhibitor (0–150 M). (B)
Immunostaining of the samples analyzed in lanes 1–3 of A revealed the presence of - and -chain-related ligated polymers, marked X1–X5.
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-chain population in plasma (Mosesson et al., 1972a; Wolfen-
stein-Todel and Mosesson, 1980; Francis et al., 1980; Chung
and Davie, 1984; Fornace et al., 1984). Multiple spots were
observed for the - and -chains, consistent with the results of
Teige et al., 1983; Carrell et al., 1983; Murthy and Lorand,
1990; and Gron et al., 1993. Immunostaining with the anti--
chain antibody revealed several spots for the three major start-
ing -chain species and two for the -chain derivatives at the
-chain position. Small amounts of -dimers were also present
in the control fibrinogen.
Protein staining of the ligated fibrin transblot revealed the
depletion of nearly all the monomeric  and most of the
major starting -chains. The formation of two species of
-dimers with pI values similar to those of the monomeric
 and  chains indicates homologous dimerization (i.e., the
formation of – and – structures), which was also
observed by Francis et al., 1980. Several higher-molecular-
weight ligated polymers were seen with pI values similar to
those of the dominant -dimer species and electrophoretic
Mr values comparable to those of bands X2–X5 in Fig. 3 B.
Inasmuch as these stained only with the -chain-specific
antibody but not with the antibody to the -chain, they seem
to represent various homopolymers of -chains. The small-
est of these polymers had an Mr value of a -tetramer. Two
additional spots were detected with pI values slightly more
alkaline than those of the homologous -polymers and with
molecular masses comparable to those of bands X3 and X4
in Fig. 3 B. These spots reacted with antibodies to both the
- and -chains and could be identified as hybrid ligated
chain products. Clearly, as indicated by the vertical streaks
at the upper right-hand corners of the transblots, a number
of other ligated species must have been produced in the
reaction of fibrin with FXIIIa. These, however, failed to
enter the gel during isoelectric focusing.
Effect of cross-link inhibition on fibrin clot rigidity
The rigidities (G) of fibrin clots having compositions cor-
responding to those examined by electrophoretic techniques
FIGURE 4 Densitometric scans of the lanes
from Fig. 3 A. The percentages of ligated chains
were calculated relative to those in lane 3 of Fig.
3 A. The percentages of  and  monomers were
calculated relative to those in lane 2. The amounts
of monomers and cross-links were normalized to
the percentages of  monomers in each lane. The
percentages in the absence of inhibitor (lane 3) are
represented by the broken lines.
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in Fig. 3 were measured in the VOR Rheometer. With
increasing concentrations of the FXIIIa inhibitor, the G
values exhibited by the clots (measured at 2 h of clotting)
decreased from 135 Pa to a plateauing average of 45 Pa
(Fig. 7). A minimum 32-fold molar excess of inhibitor over
the added FXIIIa enzyme (i.e., 1 M inhibitor) was required
to reduce clot stiffness to this value.
The range of inhibitor concentrations that had the greatest
effects on G (0 to 1 M) seems to best correlate with
changes in the amounts of the higher-molecular-weight
ligated species (bands X1–X5 in Fig. 3 A) but not with
changes in the amounts of -dimer. Moreover, the high
inhibitor concentrations (1 M) needed to prevent
-dimer formation brought about no further decreases in G.
The relationship between the measured storage moduli of
the clots (Fig. 7) and the amounts of the various ligated
species as detected by SDS-PAGE (Fig. 4) is summarized in
Fig. 8.
DISCUSSION
FXIIIa-induced clot stabilization produces no changes in the
general appearance of fibrin networks observed under elec-
tron microscopy (Muller et al., 1984; Ryan et al., 1999) or
in the mass-length ratios of fibers examined in turbidity
experiments (Carr et al., 1987). The stiffening of clots
produced by ligations, therefore, does not appear to origi-
nate from alterations in network morphology (i.e., the for-
mation of new branchpoints or increased lateral aggrega-
tion), but most likely from the stiffening of the individual
fibrin fibers already existing in the clot.
FIGURE 5 Development of ligated species with time. Reaction mixtures
containing fibrinogen (6 M), thrombin (3.5 NIHU/ml), CaCl2 (5 mM),
FXIIIa (31 nM), and DMSO (0.3%) were clotted at 37°C for various
periods of time and analyzed by reducing SDS-PAGE.
FIGURE 6 Analysis of fibrin chains by two-di-
mensional gel electrophoresis. Noncross-linked and
cross-linked fibrin samples, of the same composition
as those in lanes 2 and 3 of Fig. 3 A, were examined
by protein staining and immunostaining with - and
-chain-specific antibodies.
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The ability to control the formation of -dimers by use of
the synthetic inhibitor of FXIIIa has enabled us to clearly
demonstrate that -dimerization by the FXIIIa-catalyzed
reaction, by itself, is not sufficient to enhance fiber stiffen-
ing. Previous investigators (Shen et al., 1974; 1975) had
proposed the same idea but were unable to clearly demon-
strate the effect of -dimerization on clot rigidity indepen-
dent from the clot stiffening effects of calcium ions. The
linkage of fibrin molecules by -chain dimerization takes
place very early in clotting and may only initially function
to secure the linear assembly of fibrin molecules without
affecting protofibril rigidity. Ligations between -chains are
believed to be oriented longitudinally between the ends of
fibrin molecules (Fig. 9 A) or transversally between mole-
cules of different fibrin strands (Fig. 9 B). Any bending or
movement of double-stranded protofibrils between one an-
other would theoretically not be restricted by the formation
of longitudinally oriented -dimers alone (Fig. 9 A). Inter-
protofibrillar movement would also not be restricted by
transverse cross-linking if dimeric -chain ligations were
formed only between molecules of the same double-
stranded protofibrils (Fig. 9 B). It is undetermined whether
transverse ligations occur between different protofibrils
(Fig. 9 C) or whether a combination of longitudinally ori-
ented and transverse ligations are formed (Fig. 9 D). Any
stiffening effects potentially imparted by the ligations of
-dimers, however, may be dampened by the inherent flex-
ibility of the fibrin molecule, which has been considered by
several investigators (Cavazza et al., 1981; Hantgan, 1982;
Weisel et al., 1987; Acuna et al., 1987; Hunziker et al.,
1988; Montejo et al., 1992).
In our experiments, generation of ligated clot rigidity was
closely related to the depletion of -chain monomers and
the development of higher-molecular-weight ligated species
(X1–X5; Fig. 8). Augmentation of G values was strongly
associated with the formation of species X4 (pq-hybrids
and possibly n-polymers) and, to a lesser degree, with that
of X5 (-tetramers and n-polymers). The appearances of
species X1 (of unknown composition), X2 (-multimers,
possibly pq-hybrids and/or n-polymers), and X3 (pq-
hybrids, -multimers, possibly n-polymers) coincided with
FIGURE 7 Effect of the synthetic inhibitor of FXIIIa on clot rigidity.
Clots were formed at 37°C from solutions of fibrinogen (6 M), thrombin
(3.5 NIHU/ml), FXIIIa (31 nM), CaCl2 (5 mM), DMSO (0.3%), and
inhibitor (0–150 M). Values for the storage modulus (G) were measured
at 2 h of clotting.
FIGURE 8 Effect of various ligated species on clot rigidity. The percentages of cross-linked species and monomeric fibrin chains found in clots analyzed
by reducing SDS-PAGE (from Fig. 4) were correlated with the rigidities of clots of the same composition examined by rheometry (from Fig. 7). The
stiffness of a nonligated clot was estimated from Fig. 7 to be 45 Pa (arrows).
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increases in G but did not seem to be necessary for the
development of clot rigidities up to at least 115, 100,
and 70 Pa, respectively. The functional roles of these
higher-molecular-weight ligated chain polymers in strength-
ening the fibrin network are possibly interdependent and
would be difficult to separate from each other.
Further demonstration of the significance of the larger
ligated chain types in enhancing clot rigidity is seen in the
approximately twofold reduction in G of clots in which the
formation of species X1–X5 was inhibited by the FXIII-
directed IgG (Fig. 1). The physiological importance of these
ligated species is demonstrated by the hemorrhagic tenden-
cies of the patient from whom the IgG was derived (Lorand
et al., 1999). Despite the nearly complete ligation of
-chains in clots formed in the presence of this antibody, the
rigidity of clots formed with the IgG was only slightly
higher than that of clots in which no -chain ligations were
present. This small elevation of G caused by the action of
FXIIIa can most likely be attributed to the formation of low
amounts of the X3–X5 species rather than the dimeric
cross-linking of -chains.
The means by which the higher-order ligated species
enhance fibrin network stiffness is unknown. Gamma-mul-
timers (Fig. 9 E) are thought to form at fibrin network
branchpoints or at sites of lateral fiber associations (Moses-
son et al., 1989), and the increased network rigidity result-
ing from their development may point to the significance of
fibrin strand thickness and branchpoint reinforcement in
enhancing clot rigidity. The configuration of pq-hybrids
and n-polymers among the fibrin fibers is potentially com-
plex, but the mechanism by which the fibrin network is
strengthened by these ligations could also be similar to that
used by the -multimers. Unlike the cross-linked -dimers,
these higher-order ligated chain species have the ability to
form linkages between more than two molecules of a fiber
and have the potential to secure several protofibrils together,
thus restricting interfibril movement and decreasing fiber
flexibility.
Although -chain dimerization by itself appears to have
no direct affect on clot rigidity, the ligating of -chains is
likely to provide the necessary structural framework for the
later-developing, higher-order ligated chain species to en-
hance network stiffness. The production of ligated -dimers
is believed to accelerate the ligating of 2-hybrid polymers
(Shainoff et al., 1991) and is also thought to be necessary
for the formation of -multimers (Siebenlist and Mosesson,
1992).
Rheological values in this investigation were measured in
a relatively small strain regime (0.1), in which changes in
strain have little effect on clot structure or rigidity (Carr et
al., 1976; Bale and Ferry, 1988; Janmey et al., 1983). At
higher strains (0.1), the possibility exists that the contri-
butions of the -dimers and other cross-linked chain species
to clot rigidity may be more significant. The roles of indi-
vidual ligated species at these strains are, as yet, unknown.
In conclusion, our study demonstrates 1) the potential
importance of the role of pq-hybrids, -multimers, and
n-polymers in enhancing the ability of a clot to withstand
mechanical stresses; 2) the absence of an effect on clot
rigidity from dimeric -chain cross-linking alone; and 3) the
effectiveness of the synthetic, active site-directed inhibitor
of FXIIIa as an agent for controlling ligations. Elucidation
of the structural origins of the FXIIIa-catalyzed cross-link-
ing effects on clot rheological behavior is significant with
regard to the expanding clinical use of rheological methods
for evaluating the hemostatic status of patients (Zuckerman
et al., 1981; Kang et al., 1985; Tuman et al., 1994; Ben-Ari
et al., 1997; Kaufmann et al., 1997; Sharma et al., 1997).
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